Assessing How Consumers Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized Clinical Trial

被引:21
|
作者
Woloshin, Steven [1 ,2 ]
Dewitt, Barry [3 ,4 ]
Krishnamurti, Tamar [5 ]
Fischhoff, Baruch [3 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Lebanon, NH 03756 USA
[2] Lisa Schwartz Fdn Truth Med, Norwich, VT USA
[3] Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA
[4] Lund Univ, Dept Clin Sci, Med Eth, Lund, Scania, Sweden
[5] Univ Pittsburgh, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA
基金
美国医疗保健研究与质量局;
关键词
D O I
10.1001/jamainternmed.2021.8075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The US Food and Drug Administration (FDA) authorized SARS-CoV-2 rapid at-home self-test kits for individuals with and without symptoms. How appropriately users interpret and act on the results of at-home COVID-19 self-tests is unknown. OBJECTIVE To assess how users of at-home COVID-19 self-test kits interpret and act on results when given instructions authorized by the FDA, instructions based on decision science principles, or no instructions. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted of 360 adults in the US who were recruited in April 2021 to complete an online survey on their interpretation of at-home COVID-19 self-test results. Participants were given 1 of 3 instruction types and were presented with 1 of 4 risk scenarios. Participants were paid $5 and had a median survey completion time of 8.7 minutes. Data analyses were performed from June to July 2021. INTERVENTION Participants were randomized to receiving either the FDA-authorized instructions (authorized), the intervention instructions (intervention), or no instructions (control), and to 1 of 4 scenarios: 3 with a high pretest probability of infection (COVID-19 symptoms and/or a close contact with COVID-19) and 1 with low pretest probability (no symptoms and no contact). The intervention instructions were designed using decision science principles. MAIN OUTCOMES AND MEASURES Proportion of participants in the high pretest probability scenarios choosing to quarantine per federal recommendations and perceived probabilities of infection given a negative or positive COVID-19 test result. A Bonferroni correction accounted for multiple comparisons (3 instruction types x 4 scenarios; alpha = 0.004). RESULTS After excluding 22 individuals who completed the survey too quickly, the responses of 338 participants (median [IQR] age, 38 [31 to 48] years; 154 (46%) women; 215 (64%) with a college degree or higher) were included in the study analysis. Given a positive test result, 95%(322 of 338; 95% CI, 0.92 to 0.97) of the total participants appropriately chose to quarantine regardless of which instructions they had received. Given a negative test result, participants in the high pretest probability scenarios were more likely to fail to quarantine appropriately with the authorized instructions (33%) than with the intervention (14%; 95% CI for the 19% difference, 6% to 31%; P =.004) or control (24%; 95% CI for the 9% difference, -4% to 23%; P =.02). In the low pretest probability scenario, the proportion choosing unnecessary quarantine was higher with the authorized instructions (31%) than with the intervention (22%; 95% CI for the 9% difference, -14% to 31%) or control (10%; 95% CI for the 21% difference, 0.5% to 41%)-neither comparison was statistically significant (P =.05 and P =.20 respectively). CONCLUSIONS AND RELEVANCE The findings of this randomized clinical trial indicate that at-home COVID-19 self-test kit users relying on the authorized instructions may not follow the Centers for Disease Control and Prevention's quarantine recommendations, producing unintended risks and unnecessary disruptions. Redesigned instructions that follow decision science principles may improve compliance.
引用
收藏
页码:332 / 341
页数:10
相关论文
共 50 条
  • [1] Increased availability to at-home COVID-19 test kits results in increased calls to the poison center
    Doughertya, Michelle
    Mahera, Margaret
    Marraffab, Jeanna M.
    Storkb, Christine
    Calleoa, Vincent
    CLINICAL TOXICOLOGY, 2022, 60 : 71 - 71
  • [2] Salient beliefs related to secondary distribution of COVID-19 self-test kits within social networks
    Bien-Gund, Cedric H.
    Sarbaugh, Molly
    Perrine, Lily
    Dugosh, Karen
    Gross, Robert
    Fishman, Jessica
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [3] How to promote repurchase intention toward Covid-19 antigen test kits: Evidence fromThai consumers
    Kim, Long
    Chouykaew, Thanapa
    Pongsakornrungsilp, Siwarit
    Jindabot, Teerasak
    Lee, Sangwon
    INNOVATIVE MARKETING, 2023, 19 (01) : 186 - 196
  • [4] At-Home Versus Onsite COVID-19 School-based Testing: A Randomized Noninferiority Trial
    Kiene, Susan M.
    McDaniels-Davidson, Corinne
    Lin, Chii-Dean
    Rodriguez, Tasi
    Chris, Nicole
    Bravo, Rebecca
    Moore, Vernon
    Snyder, Tom
    Arechiga-Romero, Marisela
    Famania-Martinez, Lynnette
    Carbuccia, Jennifer
    Pinuelas-Morineau, Rachel
    Oren, Eyal
    PEDIATRICS, 2023, 152
  • [5] Are self-test kits still relevant post COVID-19 pandemic? Qualitative study on working adults' perceptions
    Lee, Gladys Yu Lin
    Lim, Raymond Boon Tar
    INFECTION DISEASE & HEALTH, 2024, 29 (02) : 73 - 80
  • [6] Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial
    Pottecher, Julien
    Raffi, Francois
    Jandrot-Perrus, Martine
    Binay, Sophie
    Comenducci, Andrea
    Desort-Henin, Violaine
    Francois, Deborah
    Gharakhanian, Shahin
    Labart, Marilyn
    Meilhoc, Adeline
    Toledano, Elie
    Pletan, Yannick
    Avenard, Gilles
    Sato, Victor H.
    PLOS ONE, 2024, 19 (06):
  • [7] Outreach to Low-Income Homebound Older Adults to Increase Access to COVID-19 Self-Test Kits, Missouri, 2022
    Skinner, Karen E.
    Stoever, Anneliese
    Zakibe, John R.
    Butler, Taylor
    Kreuter, Matthew W.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2024, 114 : S65 - S68
  • [8] Implementation of an At-home Blood Pressure Measurement Protocol in a Hypertension Management Clinical Trial During the COVID-19 Pandemic
    Miller, Hailey N.
    Berger, Miriam B.
    Askew, Sandy
    Trefney, Elizabeth
    Tyson, Crystal
    Svetkey, Laura
    Bennett, Gary G.
    Steinberg, Dori M.
    JOURNAL OF CARDIOVASCULAR NURSING, 2022, 37 (05) : 475 - 481
  • [9] Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial
    Morales-Ortega, Alejandro
    Farfan-Sedano, Ana Isabel
    San Martin-Lopez, Juan Victor
    Escriba-Barcena, Almudena
    Jaenes-Barrios, Beatriz
    Madronal-Cerezo, Elena
    Llarena-Barroso, Cristina
    Mesa-Plaza, Nieves
    Frutos-Perez, Begona
    Ruiz-Giardin, Jose Manuel
    Duarte-Millan, Miguel Angel
    Piedrabuena-Garcia, Sara Isabel
    Carpintero-Garcia, Lorena
    Canalejo-Castrillero, Eduardo
    Mora-Hernandez, Belen
    Garcia-Parra, Carlos Javier
    Magro-Garcia, Hector Agustin
    Algaba-Garcia, Alicia
    Hernandez-Muniesa, Belen
    Nasarre-Lopez, Berta
    Ontanon-Nasarre, Ana
    Dominguez-Garcia, Maria Jesus
    Gomez-Santos, Dulce
    Prieto-Menchero, Santiago
    Garcia de Tena, Jaime
    Bermejo, Fernando
    Garcia-Gil, Mario
    Gonzalo-Pascua, Sonia
    Bernal-Bello, David
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [10] Immunochromatographic Self-Test Kits for COVID-19 Detection Verification of Lay Person Safe Test Realization: Cluster Study on Efficacy and Safety in Northern and Central Germany
    Braun-Muenker, Myriam
    Kesselring, Regina
    Ecker, Felix
    Dettmer, Markus
    Bonni, Marcel
    Doll, Dietrich
    PHARMAZEUTISCHE INDUSTRIE, 2022, 84 (11): : 1336 - 1345